| Date Filed | Type | Description |
| 10/06/2023 |
4
| Megna Michael R (CHIEF ACCOUNTING OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Paid exercise price by delivering 52 shares
@ $16.01, valued at
$832.5
Exercised 175 options to buy
@ $0 |
|
| 08/18/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/10/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 6.1% stake in Kiniksa Pharmaceuticals, Ltd. |
| 08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/27/2023 |
4
| Paolini John F. (CHIEF MEDICAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Sold 5,200 shares
@ $18.01, valued at
$93.7k
Sold 16,168 shares
@ $19.25, valued at
$311.2k
Sold 7,632 shares
@ $19.69, valued at
$150.3k
Exercised 29,000 options to buy
@ $1.86, valued at
$53.9k
|
|
| 07/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
4
| Malley Thomas (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 07/03/2023 |
4
| McCain Tracey L (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Levy Richard S (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Popovits Kimberly J (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Cole G Bradley (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Quart Barry D (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Exercised 5,000 options to buy
@ $0 |
|
| 06/08/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 8,746 shares
@ $0
Granted 52,472 options to buy
@ $15.19, valued at
$797k
Granted 52,472 options to buy
@ $15.19, valued at
$797k
|
|
| 06/08/2023 |
4
| Malley Thomas (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/08/2023 |
4
| Popovits Kimberly J (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/08/2023 |
4
| Levy Richard S (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/08/2023 |
4
| Quart Barry D (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/08/2023 |
4
| Cole G Bradley (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/08/2023 |
4
| McCain Tracey L (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 26,236 options to buy
@ $15.19, valued at
$398.5k
Granted 4,373 options to buy
@ $0 |
|
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
4
| Paolini John F. (CHIEF MEDICAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 38,974 options to buy
@ $10.76, valued at
$419.4k
Granted 6,496 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Megna Michael R (CHIEF ACCOUNTING OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 20,459 options to buy
@ $10.76, valued at
$220.1k
Granted 10,230 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Moat Ross (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 38,668 options to buy
@ $10.76, valued at
$416.1k
Granted 6,445 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Ragosa Mark (CFO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 42,050 options to buy
@ $10.76, valued at
$452.5k
Granted 7,000 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Tessari Eben (COO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 42,544 options to buy
@ $10.76, valued at
$457.8k
Granted 7,091 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Patel Sanj K (CHAIRMAN & CEO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 155,500 options to buy
@ $10.76, valued at
$1.7M
Granted 25,925 options to buy
@ $0 |
|
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2023 |
4
| Megna Michael R (CHIEF ACCOUNTING OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 704 shares
@ $9.56, valued at
$6.7k
Paid exercise price by delivering 221 shares
@ $11.46, valued at
$2.5k
Paid exercise price by delivering 635 shares
@ $11.12, valued at
$7.1k
Exercised 774 options to buy
@ $0
Exercised 2,163 options to buy
@ $0 |
|
| 03/20/2023 |
4
| Patel Sanj K (CHAIRMAN & CEO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Paid exercise price by delivering 1,929 shares
@ $11.46, valued at
$22.1k
Paid exercise price by delivering 3,523 shares
@ $11.12, valued at
$39.2k
Exercised 6,569 options to buy
@ $0
Exercised 12,002 options to buy
@ $0 |
|
|